Endothelin Receptors

21 Items

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. ETA-receptor Antagonist

    Zibotentan (ZD4054)is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM).
  2. ETAR/ETBR inhibitor

    Bosentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors.
  3. EndothelinA receptor antagonist

    Ambrisentan functions as an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA).
  4. Endothelin antagonist

    Avosentan (SPP301) is a potent and highly selective ETA receptor blocker.
  5. Endothelin receptor antagonist

    Macitentan is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
  6. ETA receptor antagonist

    Sitaxentan sodium (TBC-11251) is a selective endothelin receptor-A antagonist with IC50 and Ki of 1.4 nM and 0.43 nM, respectively.
  7. endothelin receptor modulator

    Endothelin Mordulator 1 is a endothelin receptor modulator, used for the research of endothelin-mediated disorders.
  8. endothelin receptor agonist

    RO462005 is an endothelin receptor selective agonist.
  9. ETA/ETB antagonist

    PD-159020 is a non-selective ETA/ETB antagonist, with IC50s of 30 and 50 nM for hETA and hETB, respectively.
  10. ETBR antagonist

    IRL-2500 is a potent, selective ETBR antagonist. It shows some selectivity for ETB receptors (IC50 values are 1.3 and 94 nM for ETB and ETA receptors respectively).
  11. ETA antagonist

    Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer, including non-small cell lung cancer. It is an endothelin receptor antagonist selective for subtype A (ETA).
  12. ETBR antagonist

    BQ-788 sodium salt is a selective ETBR (Endothelin receptor B ) antagonist.
  13. Endothelin-2, human, endogenous peptide found predominately in the kidney and intestine. Displays similar selectivity for ETA and ETB endothelin receptors.
  14. ET-A and ET-B antagonist

    Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
  15. Endothelin antagonist receptor

    Atrasentan hydrochloride is an endothelin antagonist receptor (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer.
  16. ETA receptor antagonist

    BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2.
  17. angiotensin II and endothelin A receptor antagonist

    Sparsentan (RE-021) is a highly potent dual angiotensin II and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively.
  18. endothelin (ET) receptor antagonist

    Tezosentan (RO 610612) is an endothelin (ET) receptor antagonist, with pA2s of 9.5, 7.7 for ETA and ETB receptors, respectively.
  19. endothelin A (ETA) receptor antagonist

    Darusentan is a selective endothelin A (ETA) receptor antagonist.
  20. endothelin ETA and ETB receptor antagonist

    Macitentan n-butyl analogue is a n-butyl analogue of Macitentan. Macitentan is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
  21. dual ETA/ETB antagonist

    Aprocitentan (ACT-132577) is the major and pharmacologically active metabolite of Macitentan. Aprocitentan is dual ETA/ETB antagonist with IC50s of 3.4 nM and 987 nM, and pA2 valus of 6.7 and 5.5, respectively.

21 Items

per page
Set Descending Direction